Plain-English translation of NCT04444128 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing a specialized heart imaging technique called T1 mapping to detect early signs of heart disease that aren't visible on standard heart scans. Researchers want to understand how this imaging method can help identify people at risk for conditions like myocarditis, heart failure, and heart muscle scarring—especially in people who may have had inflammation from COVID-19 or other causes. The goal is to create a clear reference guide so doctors can use this imaging to spot disease before serious problems develop.
Current heart imaging methods sometimes miss early signs of disease, particularly in people who may have subtle heart inflammation from infections like COVID-19. This study exists to establish reliable standards for this new imaging technique so it can become a routine tool to identify people at risk and prevent serious heart problems down the road.
You likely qualify if…
You likely don't qualify if…
You will come in for a heart imaging scan using a magnetic resonance imaging (MRI) machine that takes detailed pictures of your heart muscle. The scan may include an injection of contrast dye to help the images show more detail. The whole visit will likely take 1–2 hours, and you won't need to stay overnight. Researchers will compare your results to others to build a reference guide for what healthy and unhealthy heart tissue looks like on these scans.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Germany